Prudential Financial Inc. increased its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 154.4% during the first quarter, according to its most recent filing with the SEC. The fund owned 562,867 shares of the medical instruments supplier’s stock after buying an additional 341,575 shares during the period. Prudential Financial Inc. owned approximately 0.98% of OraSure Technologies worth $7,278,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new stake in shares of OraSure Technologies during the fourth quarter valued at approximately $2,076,000. State Street Corp boosted its stake in shares of OraSure Technologies by 6.3% in the fourth quarter. State Street Corp now owns 1,346,519 shares of the medical instruments supplier’s stock valued at $11,823,000 after buying an additional 79,922 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of OraSure Technologies by 29.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,494,674 shares of the medical instruments supplier’s stock valued at $21,903,000 after buying an additional 569,993 shares during the last quarter. Trexquant Investment LP boosted its stake in shares of OraSure Technologies by 103.1% in the fourth quarter. Trexquant Investment LP now owns 92,707 shares of the medical instruments supplier’s stock valued at $814,000 after buying an additional 47,072 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of OraSure Technologies during the fourth quarter valued at approximately $394,000. Institutional investors and hedge funds own 88.02% of the company’s stock.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

OraSure Technologies, Inc. (NASDAQ OSUR) opened at 14.94 on Friday. OraSure Technologies, Inc. has a 52 week low of $5.57 and a 52 week high of $15.90. The firm has a 50-day moving average price of $14.85 and a 200 day moving average price of $11.52. The firm has a market capitalization of $862.96 million, a price-to-earnings ratio of 28.62 and a beta of 1.60.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.04. The firm had revenue of $32.55 million for the quarter, compared to analyst estimates of $31.19 million. OraSure Technologies had a return on equity of 16.06% and a net margin of 22.57%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company earned $0.04 EPS. On average, equities research analysts forecast that OraSure Technologies, Inc. will post $0.42 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/06/18/prudential-financial-inc-has-7-28-million-position-in-orasure-technologies-inc-osur.html.

OSUR has been the topic of several analyst reports. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, April 12th. Jefferies Group LLC upped their target price on OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, May 4th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $12.04.

In other news, SVP Mark L. Kuna sold 36,413 shares of OraSure Technologies stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $15.11, for a total value of $550,200.43. Following the sale, the senior vice president now directly owns 92,904 shares in the company, valued at approximately $1,403,779.44. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Douglas A. Michels sold 361,216 shares of OraSure Technologies stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $15.08, for a total value of $5,447,137.28. Following the completion of the sale, the chief executive officer now owns 881,620 shares in the company, valued at $13,294,829.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 929,859 shares of company stock worth $13,926,644. Corporate insiders own 7.80% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.